Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Nina Prokoph(MRC Laboratory of Molecular Biology), Suzanne D. Turner(MRC Laboratory of Molecular Biology)
Cited by 86
Related Papers
Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|American Journal Of Pathology|2019|54
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
|Nature Communications|2019|42